Quarterly report pursuant to Section 13 or 15(d)
Cover
Document and Entity Information
Financial Statements
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS (Parenthetical)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Notes to Financial Statements
General
Summary of Significant Accounting Policies
Revenue
Profit/(Loss) per share
Accumulated other comprehensive loss
Fair value measurements
Marketable securities - available-for-sale debt securities
Other current assets
Operating Leases
Accrued expenses and other current liabilities
Contingencies and commitments
Share-based compensation
Stockholders' equity
Restructuring
Subsequent events
Accounting Policies
Summary of Significant Accounting Policies (Policies)
Notes Tables
Revenue (Tables)
Profit/(Loss) per share (Tables)
Accumulated other comprehensive loss (Tables)
Fair value measurements (Tables)
Marketable securities - available-for-sale debt securities (Tables)
Other current assets (Tables)
Operating Leases (Tables)
Accrued expenses and other current liabilities (Tables)
Share-based compensation (Tables)
Restructuring (Tables)
Notes Details
General (Details)
Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)
Summary of Significant Accounting Policies - Accounts receivable (Details)
Revenue - Revenue from contracts with customers (Details)
Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details)
Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details)
Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details)
Profit/(Loss) per share - Basic and diluted income (loss) per share (Details)
Profit/(loss) per share - Antidilutive shares (Details)
Accumulated other comprehensive loss (Details)
Fair value measurements (Details)
Marketable securities - Available-for-sale debt securities (Details)
Marketable securities - Available-for-sale debt securities - Unrealized loss position (Details)
Other current assets (Details)
Operating Leases (Details)
Operating Leases - Maturities (Details)
Accrued expenses and other current liabilities (Details)
Contingencies and commitments - Universal Cells Research, Collaboration and License Agreement and Co-development and Co-commercialization agreement (Details)
Contingencies and commitments - MD Anderson Strategic Alliance (Details)
Share-based compensation - Share-based Compensation Expense (Details)
Share-based compensation - Options (Details)
Stockholders equity - Offerings (Details)
Restructuring (Details)
Restructuring - Movements in Provision (Details)
Subsequent events (Details)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS
403 Forbidden
Forbidden
You don't have permission to access this resource.